Early Treatment of the Inflammatory Stage of COVID-19 and its Rationale

COVID-19 is typically an acute infection caused by SARS-CoV-2 virus that lasts 2-3 weeks. However, in some instances the disease may worsen and lead to Acute Respiratory Distress Syndrome (ARDS) and multisystem damage that can result in long term disability or even death if not treated early and effectively.

This article focuses on the early inflammatory phase of COVID-19, which typically starts about a week after the onset of first symptoms associated with the initial viral stage. A readily accessible treatment option comprising well-known glucocorticoids, antihistamines, leukotriene antagonists and anticoagulants is included, and its rationale is given. This treatment option is especially relevant for general practitioners and emergency room clinicians and can be initiated prior to the need for hospitalization and in most cases may also prevent it.

This article, authored by Elizabeth Bastian; Niel A. Karrow; Ondrej Halgas and Kanji Nakatsu, who are all based in Canada, seeks to particularly understand the rationale and nature of the treatments developed by Dr Shankara Chetty, from South Africa, also known as 8th Day Therapy for COVID-19. The authors acknowledge Jean-Pierre Kiekens, independent policy expert, for having convened the team and facilitated the project, and Dr. Shankara Chetty, Medical Doctor, for having inspired this work and having offered feedback on a draft of the article.

Access full article at: https://zenodo.org/record/5033246

See our previous article about Dr Chetty’s 8th Day Therapy: